Menstrual insufficiency caused by deficiency of qi and blood
Conditions
Interventions
Treatment Group:Bazhen Teabag
Control Group:Bazhen Wan
Sponsors
Chengdu University of Traditional Chinese Medicine Affiliated Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for oligomenorrhea; 2. Meet the diagnostic criteria for qi and blood deficiency syndrome; 3. Age between 18 and 40 years old; 4. Agree to conduct clinical trials and sign an informed consent form.
Exclusion criteria
Exclusion criteria: Anyone who falls under any of the following circumstances will not be selected as a subject. 1. Patients with prolonged menstrual periods; 2. Patients with endometrial lesions intrauterine adhesions premature ovarian failure uterine fibroids (larger than 3cm) adenomyosis pituitary tumors and thyroid dysfunction after examination; 3. Those who have used drugs or methods that have therapeutic effects on oligomenorrhea within one month before the study and those who have used hormone drugs and contraceptive pills for treatment within three months; 4. Those with a history or present medical history of serious cardiovascular disease digestive system disease hematopoietic system disease mental and neurological system disease etc. whom the researcher deems unsuitable to participate in this clinical trial; 5. Abnormal liver function (alanine aminotransferase (ALT) aspartate aminotransferase (AST)>1.5 times the upper limit of normal values) abnormal kidney function (creatinine (Cr) blood urea nitrogen (BUN)>normal values) and clinically significant as determined by researchers; 6. Individuals with allergic constitution or multiple drug allergies; 7. Those who plan to conceive during the medication period and within one month after stopping the medication and those who cannot strictly use contraception as required; 8. Patients who are unable to cooperate or are currently participating in other drug trials; 9. Patients with ovarian dysfunction caused by iatrogenic factors; 10. Researchers determine that individuals are not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TCM syndrome curative effect;Pictorial Blood Loss Assessment Chart; | — |
Secondary
| Measure | Time frame |
|---|---|
| Follicle stimulating hormone;Estradiol;Progesterone;Testosterone;Luteinizing hormone;Pituitary prolactin; | — |
Countries
China
Contacts
Public ContactYan Wang
Chengdu University of Traditional Chinese Medicine Affiliated Hospital
Outcome results
None listed